Aim To evaluate the efficacy and safety of fast‐acting insulin aspart (faster aspart) vs insulin
aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII) in participants with
type 1 diabetes (T1D). Materials and Methods This was a double‐blind, treat‐to‐target,
randomized, 16‐week trial investigating CSII treatment with faster aspart (n= 236) or IAsp
(n= 236). All available information, regardless of treatment discontinuation, was used for the
evaluation of effect. Results Faster aspart was non‐inferior to IAsp regarding the change …

OBJECTIVE To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart)
compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in
adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. RESEARCH
DESIGN AND METHODS This multicenter, double-blind, treat-to-target trial randomized
participants to faster aspart (n= 546) or IAsp (n= 545). All available information, regardless of
treatment discontinuation or use of ancillary treatment, was used for evaluation of effect …